BR112019008156A2 - métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama - Google Patents
métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gamaInfo
- Publication number
- BR112019008156A2 BR112019008156A2 BR112019008156-9A BR112019008156A BR112019008156A2 BR 112019008156 A2 BR112019008156 A2 BR 112019008156A2 BR 112019008156 A BR112019008156 A BR 112019008156A BR 112019008156 A2 BR112019008156 A2 BR 112019008156A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- interferon
- prevention
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662411783P | 2016-10-24 | 2016-10-24 | |
| US62/411,783 | 2016-10-24 | ||
| PCT/IB2017/001427 WO2018078442A2 (en) | 2016-10-24 | 2017-10-24 | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019008156A2 true BR112019008156A2 (pt) | 2019-07-02 |
Family
ID=60957345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008156-9A BR112019008156A2 (pt) | 2016-10-24 | 2017-10-24 | métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3528845A2 (https=) |
| JP (3) | JP2019532970A (https=) |
| KR (2) | KR20240148970A (https=) |
| CN (1) | CN110167593A (https=) |
| AU (2) | AU2017352033A1 (https=) |
| BR (1) | BR112019008156A2 (https=) |
| CA (2) | CA3244670A1 (https=) |
| EA (1) | EA201990930A1 (https=) |
| IL (1) | IL266174B2 (https=) |
| MX (2) | MX2019004766A (https=) |
| SG (1) | SG11201903659WA (https=) |
| WO (1) | WO2018078442A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121588213A (zh) | 2015-05-07 | 2026-03-03 | 瑞典孤儿比奥维特鲁姆股份公司 | 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症 |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| WO2017186121A1 (zh) * | 2016-04-26 | 2017-11-02 | 科济生物医药（上海）有限公司 | 一种改善免疫应答细胞功能的方法 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2021185832A1 (en) | 2020-03-16 | 2021-09-23 | Swedish Orphan Biovitrum Ag | New therapeutic treatment |
| JP2023521519A (ja) * | 2020-04-06 | 2023-05-24 | セレディット エルエルシー | キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞 |
| WO2024254401A1 (en) | 2023-06-09 | 2024-12-12 | Children's Hospital Medical Center | Treatment of stem cell graft failure |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2002531466A (ja) * | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| JP5290489B2 (ja) * | 2001-11-08 | 2013-09-18 | アッヴィ・バイオセラピューティクス・インコーポレイテッド | Ｉｇｇ抗体の安定な液体医薬製剤 |
| MX2007008719A (es) * | 2005-01-27 | 2007-09-11 | Novimmune Sa | Anticuerpos anti-interferon gamma y metodos de uso de los mismos. |
| AU2006247039B2 (en) * | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
| KR101247418B1 (ko) | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| US20130142809A1 (en) * | 2011-11-23 | 2013-06-06 | Andrew A. Welcher | METHODS OF TREATMENT USING AN IFN gamma INHIBITOR |
| JPWO2015190378A1 (ja) | 2014-06-10 | 2017-04-20 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 安定なアダリムマブ水性製剤 |
| CN121588213A (zh) * | 2015-05-07 | 2026-03-03 | 瑞典孤儿比奥维特鲁姆股份公司 | 用于诊断和治疗cxcl9和其它生物标志物水平升高的患者的病症 |
-
2017
- 2017-10-24 EP EP17829009.4A patent/EP3528845A2/en active Pending
- 2017-10-24 CA CA3244670A patent/CA3244670A1/en active Pending
- 2017-10-24 WO PCT/IB2017/001427 patent/WO2018078442A2/en not_active Ceased
- 2017-10-24 CN CN201780080221.6A patent/CN110167593A/zh active Pending
- 2017-10-24 MX MX2019004766A patent/MX2019004766A/es unknown
- 2017-10-24 CA CA3041434A patent/CA3041434A1/en active Pending
- 2017-10-24 IL IL266174A patent/IL266174B2/en unknown
- 2017-10-24 AU AU2017352033A patent/AU2017352033A1/en not_active Abandoned
- 2017-10-24 SG SG11201903659WA patent/SG11201903659WA/en unknown
- 2017-10-24 KR KR1020247033365A patent/KR20240148970A/ko not_active Ceased
- 2017-10-24 EA EA201990930A patent/EA201990930A1/ru unknown
- 2017-10-24 JP JP2019521706A patent/JP2019532970A/ja not_active Withdrawn
- 2017-10-24 KR KR1020197014837A patent/KR20190071785A/ko not_active Ceased
- 2017-10-24 BR BR112019008156-9A patent/BR112019008156A2/pt unknown
-
2019
- 2019-04-24 MX MX2025012950A patent/MX2025012950A/es unknown
-
2022
- 2022-10-28 JP JP2022173528A patent/JP7562074B2/ja active Active
-
2024
- 2024-09-06 JP JP2024153940A patent/JP2024170569A/ja active Pending
- 2024-11-12 AU AU2024264563A patent/AU2024264563A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240148970A (ko) | 2024-10-11 |
| MX2025012950A (es) | 2025-12-01 |
| CA3244670A1 (en) | 2025-11-29 |
| JP2022187025A (ja) | 2022-12-15 |
| JP2019532970A (ja) | 2019-11-14 |
| AU2017352033A1 (en) | 2019-06-06 |
| MX2019004766A (es) | 2019-09-27 |
| WO2018078442A3 (en) | 2018-08-23 |
| IL266174A (en) | 2019-06-30 |
| CN110167593A (zh) | 2019-08-23 |
| CA3041434A1 (en) | 2018-05-03 |
| AU2024264563A1 (en) | 2024-11-28 |
| JP7562074B2 (ja) | 2024-10-07 |
| WO2018078442A2 (en) | 2018-05-03 |
| EA201990930A1 (ru) | 2019-11-29 |
| EP3528845A2 (en) | 2019-08-28 |
| IL266174B1 (en) | 2024-06-01 |
| KR20190071785A (ko) | 2019-06-24 |
| IL266174B2 (en) | 2024-10-01 |
| JP2024170569A (ja) | 2024-12-10 |
| SG11201903659WA (en) | 2019-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008156A2 (pt) | métodos, composições e regimes de dosagem no tratamento ou prevenção de indicações relacionadas com interferon-gama | |
| MX2016015363A (es) | Terapias de combinacion para el tratamiento de cancer. | |
| EA201792545A1 (ru) | Способы и наборы для лечения депрессии | |
| BR112019001615A2 (pt) | métodos e composições para tratar mielofibrose | |
| PH12019501010A1 (en) | Arginase inhibitor combination therapies | |
| BR112019005305A2 (pt) | compostos espirocíclicos | |
| BR112017008284A8 (pt) | Bifidobactérias ativadas e métodos para uso das mesmas | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| MX2021009899A (es) | Administracion y dosificacion de diaminofenotiazinas. | |
| MY192705A (en) | Compositions and methods for treating anemia | |
| BR112018008103A2 (pt) | análogos de celastrol | |
| MX2020006963A (es) | Composiciones y metodos para tratar anemia. | |
| BR112017007817A2 (pt) | tratamento do câncer com estimuladores imunológicos | |
| BR112017024163A2 (pt) | compostos bicíclicos | |
| BR112017021194A2 (pt) | compostos espirocíclicos | |
| MX2023007405A (es) | Regimen de cladribina para usarse en el tratamiento de formas progresivas de esclerosis multiple. | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| BR112017002061A2 (pt) | composições e regimes para tratamento bucal | |
| PH12017501120A1 (en) | Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes | |
| BR112015016992A2 (pt) | uso de agonistas de receptores alfa 7 nicotínico de acetilcolina para o tratamento, melhoria, prevenção ou demora no progresso da fadiga | |
| BR112019006504A2 (pt) | regime de dosagem de avelumabe para o tratamento de câncer | |
| BR112017004552A2 (pt) | composições farmacêuticas | |
| BR112017027692A2 (pt) | regimes de dosagem imunoterapêuticos compreendendo pomalidomida e um anticorpo anti-cs1 para tratamento do câncer | |
| MX2016014780A (es) | Metodos y composiciones de dasotralina para el tratamiento del adhd. | |
| PH12019500464A1 (en) | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: EMACO SA (CH) |
|
| B25A | Requested transfer of rights approved |
Owner name: SWEDISH ORPHAN BIOVITRUM AG (CH) |
|
| B25G | Requested change of headquarter approved |
Owner name: SWEDISH ORPHAN BIOVITRUM AG (CH) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |